- Home
- BATL vs CELU Comparison
BATL vs CELU Comparison
Compare BATL & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BATL
- CELU
- Stock Information
- Founded
- BATL 1987
- CELU 2016
- Country
- BATL United States
- CELU United States
- Employees
- BATL N/A
- CELU N/A
- Industry
- BATL Oil & Gas Production
- CELU Biotechnology: Pharmaceutical Preparations
- Sector
- BATL Energy
- CELU Health Care
- Exchange
- BATL Nasdaq
- CELU Nasdaq
- Market Cap
- BATL 40.0M
- CELU 42.2M
- IPO Year
- BATL N/A
- CELU N/A
- Fundamental
- Price
- BATL $1.35
- CELU $2.03
- Analyst Decision
- BATL
- CELU
- Analyst Count
- BATL 0
- CELU 0
- Target Price
- BATL N/A
- CELU N/A
- AVG Volume (30 Days)
- BATL 3.1M
- CELU 83.9K
- Earning Date
- BATL 08-13-2025
- CELU 05-08-2025
- Dividend Yield
- BATL N/A
- CELU N/A
- EPS Growth
- BATL N/A
- CELU N/A
- EPS
- BATL N/A
- CELU N/A
- Revenue
- BATL $191,498,000.00
- CELU $54,220,000.00
- Revenue This Year
- BATL N/A
- CELU $23.29
- Revenue Next Year
- BATL N/A
- CELU N/A
- P/E Ratio
- BATL N/A
- CELU N/A
- Revenue Growth
- BATL N/A
- CELU 138.11
- 52 Week Low
- BATL $1.05
- CELU $1.00
- 52 Week High
- BATL $6.89
- CELU $5.22
- Technical
- Relative Strength Index (RSI)
- BATL 43.09
- CELU 54.25
- Support Level
- BATL $1.21
- CELU $1.80
- Resistance Level
- BATL $3.21
- CELU $2.26
- Average True Range (ATR)
- BATL 0.46
- CELU 0.17
- MACD
- BATL -0.10
- CELU 0.02
- Stochastic Oscillator
- BATL 5.69
- CELU 57.46
About BATL Battalion Oil Corporation
Battalion Oil Corp is an independent energy company focused on the acquisition, production, exploration, and development of onshore liquids-rich oil and natural gas assets in the U.S. Its properties and drilling activities are currently focused in the Delaware Basin.
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.